Anal carcinoma: Clinical practice guidelines in oncology™

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson, Jordan D. Berlin, J. Michael Berry, Yi Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman, Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric RohrenDavid P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small, Constantinos Sofocleous, James Thomas, Alan P. Venook, Christopher Willett

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The panel believes that a multidisciplinary approach, including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology, is necessary for treating patients with anal carcinoma. Recommendations for the primary treatment of anal margin and anal canal cancer are very similar and include 5-FU/mitomycin-based RT, although small, well-differentiated anal margin lesions can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because salvage is possible. Patients with biopsy-proven evidence of locoregional progressive disease after primary treatment should undergo an APR. After complete remission of disease, patients with a local recurrence should be treated with an APR with groin dissection if they have evidence of inguinal nodal metastasis, and patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy, if limited prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with cisplatin-based chemotherapy or enrolled in a clinical trial. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

Original languageEnglish (US)
Pages (from-to)106-120
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Practice Guidelines
Groin
Carcinoma
Dissection
Clinical Trials
Anus Neoplasms
Recurrence
Drug Therapy
Radiation Oncology
Medical Oncology
Anal Canal
Mitomycin
Gastroenterology
Radiology
Fluorouracil
Cisplatin
Therapeutics
Neoplasm Metastasis
Physicians
Biopsy

Keywords

  • Anal neoplasms
  • Biopsy
  • NCCN clinical practice guidelines
  • Neoplasm staging
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Berlin, J. D., Berry, J. M., Chen, Y. J., ... Willett, C. (2010). Anal carcinoma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 8(1), 106-120. https://doi.org/10.6004/jnccn.2010.0007
Engstrom, Paul F. ; Arnoletti, Juan Pablo ; Benson, Al B. ; Berlin, Jordan D. ; Berry, J. Michael ; Chen, Yi Jen ; Choti, Michael A. ; Cooper, Harry S. ; Dilawari, Raza A. ; Early, Dayna S. ; Enzinger, Peter C. ; Fakih, Marwan G. ; Fleshman, James ; Fuchs, Charles ; Grem, Jean L. ; Knol, James A. ; Leong, Lucille A. ; Lin, Edward ; Mulcahy, Mary F. ; Rohren, Eric ; Ryan, David P. ; Saltz, Leonard ; Shibata, David ; Skibber, John M. ; Small, William ; Sofocleous, Constantinos ; Thomas, James ; Venook, Alan P. ; Willett, Christopher. / Anal carcinoma : Clinical practice guidelines in oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2010 ; Vol. 8, No. 1. pp. 106-120.
@article{3c55708685ee48b5b66662e47b45477c,
title = "Anal carcinoma: Clinical practice guidelines in oncology™",
abstract = "The panel believes that a multidisciplinary approach, including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology, is necessary for treating patients with anal carcinoma. Recommendations for the primary treatment of anal margin and anal canal cancer are very similar and include 5-FU/mitomycin-based RT, although small, well-differentiated anal margin lesions can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because salvage is possible. Patients with biopsy-proven evidence of locoregional progressive disease after primary treatment should undergo an APR. After complete remission of disease, patients with a local recurrence should be treated with an APR with groin dissection if they have evidence of inguinal nodal metastasis, and patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy, if limited prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with cisplatin-based chemotherapy or enrolled in a clinical trial. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.",
keywords = "Anal neoplasms, Biopsy, NCCN clinical practice guidelines, Neoplasm staging, Surgery",
author = "Engstrom, {Paul F.} and Arnoletti, {Juan Pablo} and Benson, {Al B.} and Berlin, {Jordan D.} and Berry, {J. Michael} and Chen, {Yi Jen} and Choti, {Michael A.} and Cooper, {Harry S.} and Dilawari, {Raza A.} and Early, {Dayna S.} and Enzinger, {Peter C.} and Fakih, {Marwan G.} and James Fleshman and Charles Fuchs and Grem, {Jean L.} and Knol, {James A.} and Leong, {Lucille A.} and Edward Lin and Mulcahy, {Mary F.} and Eric Rohren and Ryan, {David P.} and Leonard Saltz and David Shibata and Skibber, {John M.} and William Small and Constantinos Sofocleous and James Thomas and Venook, {Alan P.} and Christopher Willett",
year = "2010",
month = "1",
day = "1",
doi = "10.6004/jnccn.2010.0007",
language = "English (US)",
volume = "8",
pages = "106--120",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

Engstrom, PF, Arnoletti, JP, Benson, AB, Berlin, JD, Berry, JM, Chen, YJ, Choti, MA, Cooper, HS, Dilawari, RA, Early, DS, Enzinger, PC, Fakih, MG, Fleshman, J, Fuchs, C, Grem, JL, Knol, JA, Leong, LA, Lin, E, Mulcahy, MF, Rohren, E, Ryan, DP, Saltz, L, Shibata, D, Skibber, JM, Small, W, Sofocleous, C, Thomas, J, Venook, AP & Willett, C 2010, 'Anal carcinoma: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 1, pp. 106-120. https://doi.org/10.6004/jnccn.2010.0007

Anal carcinoma : Clinical practice guidelines in oncology™. / Engstrom, Paul F.; Arnoletti, Juan Pablo; Benson, Al B.; Berlin, Jordan D.; Berry, J. Michael; Chen, Yi Jen; Choti, Michael A.; Cooper, Harry S.; Dilawari, Raza A.; Early, Dayna S.; Enzinger, Peter C.; Fakih, Marwan G.; Fleshman, James; Fuchs, Charles; Grem, Jean L.; Knol, James A.; Leong, Lucille A.; Lin, Edward; Mulcahy, Mary F.; Rohren, Eric; Ryan, David P.; Saltz, Leonard; Shibata, David; Skibber, John M.; Small, William; Sofocleous, Constantinos; Thomas, James; Venook, Alan P.; Willett, Christopher.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. 1, 01.01.2010, p. 106-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anal carcinoma

T2 - Clinical practice guidelines in oncology™

AU - Engstrom, Paul F.

AU - Arnoletti, Juan Pablo

AU - Benson, Al B.

AU - Berlin, Jordan D.

AU - Berry, J. Michael

AU - Chen, Yi Jen

AU - Choti, Michael A.

AU - Cooper, Harry S.

AU - Dilawari, Raza A.

AU - Early, Dayna S.

AU - Enzinger, Peter C.

AU - Fakih, Marwan G.

AU - Fleshman, James

AU - Fuchs, Charles

AU - Grem, Jean L.

AU - Knol, James A.

AU - Leong, Lucille A.

AU - Lin, Edward

AU - Mulcahy, Mary F.

AU - Rohren, Eric

AU - Ryan, David P.

AU - Saltz, Leonard

AU - Shibata, David

AU - Skibber, John M.

AU - Small, William

AU - Sofocleous, Constantinos

AU - Thomas, James

AU - Venook, Alan P.

AU - Willett, Christopher

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The panel believes that a multidisciplinary approach, including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology, is necessary for treating patients with anal carcinoma. Recommendations for the primary treatment of anal margin and anal canal cancer are very similar and include 5-FU/mitomycin-based RT, although small, well-differentiated anal margin lesions can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because salvage is possible. Patients with biopsy-proven evidence of locoregional progressive disease after primary treatment should undergo an APR. After complete remission of disease, patients with a local recurrence should be treated with an APR with groin dissection if they have evidence of inguinal nodal metastasis, and patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy, if limited prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with cisplatin-based chemotherapy or enrolled in a clinical trial. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

AB - The panel believes that a multidisciplinary approach, including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology, is necessary for treating patients with anal carcinoma. Recommendations for the primary treatment of anal margin and anal canal cancer are very similar and include 5-FU/mitomycin-based RT, although small, well-differentiated anal margin lesions can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because salvage is possible. Patients with biopsy-proven evidence of locoregional progressive disease after primary treatment should undergo an APR. After complete remission of disease, patients with a local recurrence should be treated with an APR with groin dissection if they have evidence of inguinal nodal metastasis, and patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy, if limited prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with cisplatin-based chemotherapy or enrolled in a clinical trial. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

KW - Anal neoplasms

KW - Biopsy

KW - NCCN clinical practice guidelines

KW - Neoplasm staging

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=76549127064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549127064&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2010.0007

DO - 10.6004/jnccn.2010.0007

M3 - Article

C2 - 20064293

AN - SCOPUS:76549127064

VL - 8

SP - 106

EP - 120

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 1

ER -